

Authors' response to: How should we best determine the need for in-flight oxygen in patients with pulmonary arterial hypertension

We thank Burns *et al*¹ for their comments on the updated British Thoracic Society recommendations for managing passengers with respiratory disease planning air travel.² In particular, a central aim of the recommendations was to promote research in this field, and we therefore commend their recent study investigating hypoxaemia in patients with pulmonary arterial hypertension (PAH) during simulated air travel.³ The method of assessment which best serves a clinician in judging which patients with PAH require in-flight oxygen remains a challenge due to a lack of evidence. Indeed, the current recommendation that those PAH patients in New York Heart Association (NYHA) functional class III or IV should receive in-flight oxygen has only a grade D evidence base. Importantly, NYHA functional class does provide a key measure of the impact of the disease on patients and is a strong predictor of survival in PAH.⁴ In this context, the successful completion of a hypoxic challenge test (HCT) alone does not always translate to an absence of symptoms in flight for these patients.³ The question of whether NYHA functional class III–IV or HCT better predicts the requirement for in-flight oxygen in PAH, clearly remains open to debate, and we hope this will only serve to encourage further high-quality research in this area to strengthen the evidence base for future air travel guidelines.

Dinesh Shrikrishna,^{1,2} Luke Howard,³
Robina K Coker,^{1,4}

¹National Heart and Lung Institute, Imperial College London, London, UK

²Department of Respiratory Medicine, Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, UK

³National Pulmonary Hypertension Unit, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

⁴National Heart and Lung Institute, Hammersmith Hospital, London, UK

Correspondence to Dr Robina K Coker, Department of Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; robina.coker@imperial.ac.uk

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

To cite Shrikrishna D, Howard L, Coker RK, *et al.* *Thorax* 2013;**68**:680–681.

Received 18 December 2012

Accepted 5 February 2013

Published Online First 5 March 2013



► <http://dx.doi.org/10.1136/thoraxjnl-2013-203344>

Thorax 2013;**68**:680–681.

doi:10.1136/thoraxjnl-2013-203379

REFERENCES

- 1 Burns RM, Johnson MK, Church AC. How should we best determine the need for in-flight oxygen in patients with pulmonary arterial hypertension. *Thorax* 2013;**68**:680.
- 2 Shrikrishna D, Coker RK. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. *Thorax* 2011;**66**:831–3.
- 3 Burns RM, Peacock AJ, Johnson MK, *et al.* Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel. *Respir Med* 2013;**107**:298–304.
- 4 National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. *Thorax* 2008;**63**(Suppl 2):ii1–41.